News

22 June 2018

C. elegans

  • Càncer
  • Medicina Translacional

CRISPR-editing of a single aminoacid make a whole animal more resistant to cisplatin-based chemotherapy

Cisplatin is one of the chemotherapeutic agents more frequently used by oncologists to treat tumors. Cisplatin-based chemotherapy is very efficient but frequently cancer cells adjust its molecular mechanisms to become resistant to cisplatin.

20 June 2018

Drs. Gabriel Capellá, director of IDIBELL, Ernest Nadal, and Ramon Salazar, Oncobell program coordinator.

  • Càncer

Two new AECC grants for IDIBELL researchers

The Provincial Board of Barcelona of the Spanish Association Against Cancer (AECC) - Catalonia Against Cancer has granted a Research grant in oncology to Dr.

18 June 2018

The genes and cancer research group, led by Dr. Montse Sánchez-Céspedes (PEBC-IDIBELL)

  • Càncer

New discoveries towards the improvement of the immunotherapy treatment of lung cancer

In recent years, immunotherapy has been consolidated as one of the new and principal hopes in the fight against cancer. This therapeutic approach is based on the fact that our immune system is constantly watching the presence of strange presences within the body and fighting them.

12 June 2018

Alberto Villanueva and Ernest Nadal

  • Càncer

New drug against of the main types of lung cancer

The clinical application of an inhibitor of the SHP2 protein (also called PTPN11) could be effective, in the near future, in patients affected by one of the main types of lung cancer, the so-called Non-small cell lung cancer (NSCLC).

11 June 2018

The cells of a patient with MCL before (left image) and after (right image) of treatment with the new drug; inhibition of cell growth is observed.

  • Càncer

New epigenetic drug against Mantle Cell Lymphoma

A new study by doctor Manel Esteller, Director of the Epigenetics and Cancer Biology Program (PEBC) of the Bellvitge Biomedical Research Institute (IDIBELL), ICREA Researcher and Professor of Genetics at the University of Barcelona, presents an epigenetic drug capable of slowing down cell growth